Sustained virologic suppression with abacavir, emtricitabine, and crushed dolutegravir and tenofovir alafenamide in a patient with HIV and eosinophilic esophagitis

Int J STD AIDS. 2020 Mar;31(3):285-287. doi: 10.1177/0956462419895690. Epub 2020 Feb 9.

Authors

Sarah E Moore¹, Emily Huesgen², Zachary Howe²

Affiliations

¹ Department of Pharmacy Practice, Franciscan Health Indianapolis, Indianapolis, IN, USA.
² Department of Pharmacy Practice, Indiana University Health, Indianapolis, IN, USA.

PMID: 32036755
DOI: 10.1177/0956462419895690

No abstract available

Keywords: AIDS; Antiretroviral therapy; HIV; treatment.

Publication types

Case Reports

MeSH terms

Abacavir
Adult
Alanine / administration & dosage
Alanine / analogs & derivatives*
Anti-HIV Agents / administration & dosage*
Deglutition Disorders / etiology
Dideoxynucleosides / administration & dosage*
Dolutegravir
Drug Therapy, Combination
Emtricitabine / administration & dosage*
Eosinophilic Esophagitis / complications*
Eosinophilic Esophagitis / diagnosis
Female
HIV Infections / drug therapy*
HIV Infections / virology
Heterocyclic Compounds, 3-Ring / administration & dosage*
Humans
Male
Oxazines
Piperazines
Pyridones
Tenofovir / administration & dosage*
Treatment Outcome
Viral Load / drug effects*

Substances

Alanine
Anti-HIV Agents
Dideoxynucleosides
Emtricitabine
Heterocyclic Compounds, 3-Ring
Oxazines
Piperazines
Pyridones
Tenofovir
Abacavir
Dolutegravir
alafosfalin